Predictive value of serum alkaline phosphatase, tumor-specific growth factor, and macrophage migration inhibitory factor for the efficacy of immunotargeted therapy in osteosarcoma patients
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Pre-treatment serum alkaline phosphatase (ALP), tumor-specific growth factor (TSGF), and macrophage migration inhibitory factor (MIF) levels predict osteosarcoma treatment response. Higher levels indicate less effective combined immunosuppressive and targeted therapy.
Area Of Science
- Oncology
- Biomarkers
- Immunotherapy
Background
- Osteosarcoma (OS) treatment efficacy can vary.
- Identifying predictive biomarkers is crucial for personalized medicine.
Purpose Of The Study
- To evaluate serum alkaline phosphatase (ALP), tumor-specific growth factor (TSGF), and macrophage migration inhibitory factor (MIF) as predictors of treatment response in OS.
- To assess the efficacy of combined immunosuppressive (interferon-α) and targeted therapy (bevacizumab).
Main Methods
- Retrospective analysis of 161 OS patients treated with interferon-α and bevacizumab.
- Serum biomarker levels (ALP, TSGF, MIF) measured pre- and post-treatment.
- Univariate and logistic regression analyses to determine predictive value.
Main Results
- Significant post-treatment reductions in serum ALP, TSGF, and MIF observed (P<0.001).
- Elevated pre-treatment biomarker levels correlated with poorer treatment outcomes (P<0.001).
Conclusions
- Pre-treatment ALP, TSGF, and MIF levels are independent predictors of response to immunotargeted therapy in osteosarcoma.
- These biomarkers may help guide individualized treatment strategies for OS patients.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.